Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Agenus Inc AGEN

Healthcare Biotechnology
Agenus Inc., a clinical-stage biotechnology company, discovers and develops therapies to activate the body's immune system against cancer and infections in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a... see more

Current News (NDAQ:AGEN)

Agenus Announces Closing of $141M Strategic Collaboration with Zydus Lifesciences to Advance BOT+BAL and Strengthen U.S. Manufacturing Readiness

Business Wire 2 days ago

France Expands National AAC Access for Agenus' Botensilimab + Balstilimab for Ovarian Cancer and Soft-Tissue Sarcomas

Business Wire 5 days ago

Agenus Reports Deep, Durable Responses with Botensilimab + Balstilimab in Highly Refractory Ovarian Cancer, Published in JITC

Business Wire December 23, 2025

Agenus to Host End-of-Year Stakeholder Webcast Featuring GI Oncology Leaders and Progress of BOT/BAL

Business Wire November 19, 2025

Agenus Appoints Dr. José Iglesias as Chief Medical Affairs Officer to Guide Global Medical Affairs and Early-Access Programs, Including France's AAC

Business Wire November 18, 2025

Agenus Reports Q3 2025 Results Showcasing Clinical and Regulatory Advances

Business Wire November 10, 2025

Agenus to Provide Corporate Update and Third Quarter 2025 Financial Report

Business Wire November 5, 2025

Agenus Reports 39% of Patients Alive at Two-Years with BOT/BAL Across Multiple Refractory Solid Tumors at ESMO 2025

Business Wire October 17, 2025

Agenus to Host October Stakeholder Briefing Showcasing BOT/BAL Global Momentum and Post-ESMO Insights

Business Wire October 16, 2025
View More News ››

Opinion & Analysis (NDAQ:AGEN)

Seven biotech names on the upswing: 2016 small-cap biotech watchlist update

The Life Sciences Report March 11, 2016
View More Opinion ››

Bullboard Posts (NDAQ:AGEN)

Still holding this stock.

It is signalling a continuing uptrend for shareholders today and tomorrow anyway,so that you guys out there should be on-board already...
coolfooldumbguy - June 3, 2025

Buy buddy buy.

This stock is signalling a big uptrend for shareholders today and tomorrow and it should keep climbing steadily upward from this point...
coolfooldumbguy - May 12, 2025

Using technical analysis for this one.

You can see that the law firms are busy with lawsuits for all of the people who paid big bucks for this stock and are way out of the...
coolfooldumbguy - August 2, 2024

It is off the bottom for the year.

Which is a good sign for this stock,plus it is in a good spot with cancer resrarch.
coolfooldumbguy - August 2, 2024

This stock is still cheap.

It should be back up over $10 per share,not by the end of this month,but probably by the end of this year,so glta.
coolfooldumbguy - August 2, 2024

Agenus Inc. (NASDAQ:AGEN): Unlocking the Potential of Immuno

http://beyondspx.com/2024/07/31/agenus-inc-nasdaqagen-unlocking-the-potential-of-immunotherapy-combinations/
MikeTester - August 2, 2024
View more Bullboard ››

Diagnostear Technologies Inc

Diagnostear Technologies Inc

DiagnosTear Technologies Inc., an ophthalmic company, engages in developing and commercializing disruptive diagnostic ...
View More »

Podcasts